🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05683314
Recruiting Observational

A Comparison Study for Unstable Sacrum/Pelvis and Acetabular Fracture Treated With Open Reduction and Internal Fixation With Minimally Invasive Internal Fixation

NCT05683314 · tracked via the Priya Life Science China tracker
Sponsor
China Medical University Hospital
Phase
Observational
Started
2018-01-03
Last updated
2023-01-13

Condition(s) studied

Unstable Sacral/Pelvic or Acetabular Fracture

Investigational drug(s) / intervention(s)

Tranditional open reduction and internal fixation

Tranditional open reduction and internal fixation: Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey

Study summary

Unstable sacral/pelvic or acetabular fracture are severe high energy fractures Surgical intervention are necessary after patient's conditions are stable. The complexity of local anatomical structure, the nearby major vessels, organ and visceral structures make the operations difficult and in high risks.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: 1. 18 years old and above with the appropriate informed consent 2. traumatic pelvic or acetabular fracture with 2018 AO/OTA classification 3. a minimum of 48 months postoperative follow-ups Exclusion Criteria: 1. pelvic or acetabular fractures that were pathological or non-traumatic in nature 2. patients with incomplete follow-up details 3. patients who denied surgical management 4. patients who received external fixation as part of their treatment strategy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China Medical University Hospital Taichung North District Recruiting

More China Medical University Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05683314 on ClinicalTrials.gov ↗ ← All trials in China